UA109916C2 - 2-аміно-4-арилтіазольні сполуки як антагоністи trра1 - Google Patents
2-аміно-4-арилтіазольні сполуки як антагоністи trра1Info
- Publication number
- UA109916C2 UA109916C2 UAA201306497A UAA201306497A UA109916C2 UA 109916 C2 UA109916 C2 UA 109916C2 UA A201306497 A UAA201306497 A UA A201306497A UA A201306497 A UAA201306497 A UA A201306497A UA 109916 C2 UA109916 C2 UA 109916C2
- Authority
- UA
- Ukraine
- Prior art keywords
- amino
- trpa1
- trpa1 antagonists
- treating
- arylthiazole
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Даний винахід належить до 2-аміно-4-арилтіазольних похідних як TRPA (підсімейство А тимчасового рецепторного потенціалу) модуляторів. Зокрема, сполуки, описані у цій заявці, корисні для лікування чи профілактики захворювань, станів та/або розладів, модульованих TRPA1 (підсімейство А тимчасового рецепторного потенціалу, член 1). Також у цій заявці представлені способи одержання сполук, описаних у цій заявці, проміжних сполук, використаних у їх синтезі, їх фармацевтичні композиції, та способи лікування чи профілактики захворювань, станів та/або розладів, модульованих TRPA1. EMBED ISISServer (І)
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN3451MU2010 | 2010-12-20 | ||
US201061428327P | 2010-12-30 | 2010-12-30 | |
IN748MU2011 | 2011-03-16 | ||
US201161466535P | 2011-03-23 | 2011-03-23 | |
IN1569MU2011 | 2011-05-25 | ||
US201161495002P | 2011-06-09 | 2011-06-09 | |
IN2741MU2011 | 2011-09-28 | ||
US201161552076P | 2011-10-27 | 2011-10-27 | |
PCT/IB2011/003224 WO2012085662A1 (en) | 2010-12-20 | 2011-12-15 | 2-amino-4-arylthiazole compounds as trpa1 antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
UA109916C2 true UA109916C2 (uk) | 2015-10-26 |
Family
ID=46235162
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA201306497A UA109916C2 (uk) | 2010-12-20 | 2011-12-15 | 2-аміно-4-арилтіазольні сполуки як антагоністи trра1 |
Country Status (20)
Country | Link |
---|---|
US (3) | US8592398B2 (uk) |
EP (1) | EP2655377B1 (uk) |
JP (1) | JP5694560B2 (uk) |
KR (1) | KR101591153B1 (uk) |
CN (1) | CN103261201B (uk) |
AP (1) | AP3391A (uk) |
AR (1) | AR084294A1 (uk) |
AU (1) | AU2011346763B2 (uk) |
BR (1) | BR112013014692A2 (uk) |
CA (1) | CA2820448A1 (uk) |
CL (1) | CL2013001810A1 (uk) |
EA (1) | EA023141B1 (uk) |
HK (1) | HK1191008A1 (uk) |
MX (1) | MX336549B (uk) |
MY (1) | MY159059A (uk) |
PE (1) | PE20140234A1 (uk) |
SG (1) | SG191173A1 (uk) |
TW (1) | TWI515199B (uk) |
UA (1) | UA109916C2 (uk) |
WO (1) | WO2012085662A1 (uk) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2011004859A (es) | 2008-11-07 | 2011-08-03 | Massachusetts Inst Technology | Lipidoides de aminoalcohol y usos de los mismos. |
MY159059A (en) | 2010-12-20 | 2016-12-15 | Glenmark Pharmaceuticals Sa | 2-amino-4-arylthiazole compounds as trpa1 antagonists |
TW201311690A (zh) | 2011-08-09 | 2013-03-16 | Hydra Biosciences Inc | 抑制暫態受體電位離子通道trpa1 |
EP4074694A1 (en) | 2011-10-27 | 2022-10-19 | Massachusetts Institute Of Technology | Amino acid-, peptide- an polypeptide-lipids, isomers, compositions, an uses thereof |
EP2805718B1 (en) | 2012-01-17 | 2018-04-04 | EA Pharma Co., Ltd. | Heterocyclic amide derivative and pharmaceutical product containing same |
MY165622A (en) | 2012-06-08 | 2018-04-18 | Glenmark Pharmaceuticals Sa | Amides of 2-amino-4aryl thiazole compounds and their salts |
CA2884922C (en) | 2012-10-01 | 2020-11-10 | Orion Corporation | N-prop-2-ynyl carboxamide derivatives and their use as trpa1 antagonists |
US9394308B2 (en) | 2013-01-18 | 2016-07-19 | Merck Sharp & Dohme Corp. | Inhibiting the transient receptor potential A1 ion channel |
GB201309333D0 (en) * | 2013-05-23 | 2013-07-10 | Agency Science Tech & Res | Purine diones as WNT pathway modulators |
US8906951B1 (en) | 2013-06-24 | 2014-12-09 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
US9198898B2 (en) | 2013-06-24 | 2015-12-01 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
CA2926389A1 (en) | 2013-10-15 | 2015-04-23 | Glenmark Pharmaceuticals S.A. | Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent |
EP3110453A4 (en) * | 2014-02-24 | 2017-09-27 | The Johns Hopkins University | Tmem100 peptides and variants thereof and their use in treating or preventing diseases or conditions |
SI3310764T1 (sl) | 2015-06-19 | 2023-06-30 | Massachusetts Institute Of Technology | Z alkenilom substituirani 2,5-piperazindioni in njihova uporaba v sestavkih za dostavo sredstva subjektu ali celici |
FR3037956B1 (fr) * | 2015-06-23 | 2017-08-04 | Servier Lab | Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
WO2017060488A1 (en) | 2015-10-09 | 2017-04-13 | Almirall, S.A. | New trpa1 antagonists |
WO2017064068A1 (en) | 2015-10-14 | 2017-04-20 | Almirall, S.A. | New trpa1 antagonists |
CN108727400B (zh) * | 2017-05-24 | 2021-07-09 | 四川晶华生物科技有限公司 | 一种治疗肿瘤的化合物 |
US10710994B2 (en) | 2018-03-19 | 2020-07-14 | Genentech, Inc. | Oxadiazole transient receptor potential channel inhibitors |
BR112021007692A2 (pt) * | 2018-10-23 | 2021-08-10 | George Edward Hoag | composição e método para tratar os pulmões |
JP7354438B2 (ja) * | 2019-10-15 | 2023-10-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Trpa1阻害剤としてのチエノピリミドン |
JP7376706B2 (ja) * | 2019-10-15 | 2023-11-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Trpa1阻害剤としてのチエノピリミドン |
WO2021216749A1 (en) * | 2020-04-22 | 2021-10-28 | George Edward Hoag | Method for treating viral and bacterial infection through inhalation therapy |
CN111437275B (zh) * | 2020-05-14 | 2021-03-19 | 黑龙江中医药大学 | 一种用于外科手术后抗炎和镇痛的药物及其应用 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA012240B1 (ru) | 2003-04-03 | 2009-08-28 | Семафор Фармасьютикалз, Инк. | Пролекарства ингибиторов киназы pi-3 |
TW200720264A (en) | 2005-04-25 | 2007-06-01 | Lundbeck & Co As H | Pro-drugs of n-thiazol-2-yl-benzamide derivatives |
TWI423819B (zh) | 2005-12-22 | 2014-01-21 | Hydra Biosciences Inc | 用於調節trpa1功能之化合物 |
EP3184527B1 (en) | 2007-06-22 | 2020-01-29 | Eli Lilly and Company | 2,6-dioxo,-2,3-dihydro-1h-purine compounds useful for treating disorders related to the activity of the trpa1 channel |
WO2009118596A2 (en) | 2008-03-26 | 2009-10-01 | Glenmark Pharmaceuticals, S. A. | Phthalimide derivatives as trpa1 modulators |
WO2009144548A1 (en) | 2008-05-28 | 2009-12-03 | Glenmark Pharmaceuticals S.A. | Imidazo [2,1-b] purine derivatives as trpa1 modulators |
WO2010004390A1 (en) | 2008-06-17 | 2010-01-14 | Glenmark Pharmaceuticals, S.A. | Quinazoline dione derivatives as trpa1 modulators |
WO2009158719A2 (en) | 2008-06-27 | 2009-12-30 | Hydra Biosciences, Inc. | Methods and compositions for treating disorders |
TW201026700A (en) | 2008-12-22 | 2010-07-16 | Hydra Biosciences Inc | Compositions useful for treating disorders related to TRPA1 |
US8623880B2 (en) * | 2009-03-23 | 2014-01-07 | Glenmark Pharmaceuticals S.A. | Fused pyrimidine-dione derivatives as TRPA1 modulators |
UA108069C2 (uk) * | 2009-03-23 | 2015-03-25 | Гленмарк Фармасьютікалс, С.А. | Злиті піримідиндіонові похідні як модулятори trpa1 |
SG174403A1 (en) * | 2009-03-23 | 2011-10-28 | Glenmark Pharmaceuticals Sa | Isothiazolo-pyrimidinedione derivatives as trpa1 modulators |
AU2010227225A1 (en) | 2009-03-23 | 2011-09-15 | Glenmark Pharmaceuticals, S.A. | Furopyrimidinedione derivatives as TRPA1 modulators |
WO2010125469A1 (en) * | 2009-04-29 | 2010-11-04 | Glenmark Pharmaceuticals, S.A. | Pyrimidinedione-fused heterocyclic compounds as trpa1 modulators |
WO2010132838A1 (en) | 2009-05-14 | 2010-11-18 | Hydra Biosciences, Inc. | Compounds useful for treating disorders related to trpa1 |
WO2011114184A1 (en) | 2010-03-15 | 2011-09-22 | Glenmark Pharmaceuticals S.A. | Amides of heterocyclic compounds as trpa1 inhibitors |
WO2011132017A1 (en) | 2010-04-19 | 2011-10-27 | Glenmark Pharmaceuticals S.A. | Pyrido[3,4-d]pyrimidinyl acetamide derivatives as trpa1 modulators |
MY159059A (en) | 2010-12-20 | 2016-12-15 | Glenmark Pharmaceuticals Sa | 2-amino-4-arylthiazole compounds as trpa1 antagonists |
-
2011
- 2011-12-15 MY MYPI2013002240A patent/MY159059A/en unknown
- 2011-12-15 EA EA201390947A patent/EA023141B1/ru not_active IP Right Cessation
- 2011-12-15 AU AU2011346763A patent/AU2011346763B2/en not_active Ceased
- 2011-12-15 JP JP2013545528A patent/JP5694560B2/ja not_active Expired - Fee Related
- 2011-12-15 US US13/327,128 patent/US8592398B2/en not_active Expired - Fee Related
- 2011-12-15 KR KR1020137014826A patent/KR101591153B1/ko not_active IP Right Cessation
- 2011-12-15 MX MX2013006634A patent/MX336549B/es unknown
- 2011-12-15 EP EP11813377.6A patent/EP2655377B1/en not_active Not-in-force
- 2011-12-15 BR BR112013014692A patent/BR112013014692A2/pt not_active IP Right Cessation
- 2011-12-15 CA CA2820448A patent/CA2820448A1/en not_active Abandoned
- 2011-12-15 WO PCT/IB2011/003224 patent/WO2012085662A1/en active Application Filing
- 2011-12-15 SG SG2013046073A patent/SG191173A1/en unknown
- 2011-12-15 UA UAA201306497A patent/UA109916C2/uk unknown
- 2011-12-15 PE PE2013001454A patent/PE20140234A1/es not_active Application Discontinuation
- 2011-12-15 AP AP2013006906A patent/AP3391A/xx active
- 2011-12-15 CN CN201180059690.2A patent/CN103261201B/zh not_active Expired - Fee Related
- 2011-12-15 AR ARP110104687A patent/AR084294A1/es unknown
- 2011-12-19 TW TW100147051A patent/TWI515199B/zh not_active IP Right Cessation
-
2013
- 2013-06-19 CL CL2013001810A patent/CL2013001810A1/es unknown
- 2013-10-21 US US14/058,509 patent/US8889862B2/en not_active Expired - Fee Related
- 2013-10-21 US US14/058,536 patent/US9073955B2/en not_active Expired - Fee Related
-
2014
- 2014-04-30 HK HK14104181.5A patent/HK1191008A1/zh not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA109916C2 (uk) | 2-аміно-4-арилтіазольні сполуки як антагоністи trра1 | |
UA108069C2 (uk) | Злиті піримідиндіонові похідні як модулятори trpa1 | |
WO2010109334A3 (en) | Thienopyrimidinedione derivatives as trpa1 modulators | |
UA107342C2 (en) | Thienopyrimidinedione derivatives as trpa1 modulators | |
WO2009118596A3 (en) | Phthalimide derivatives as trpa1 modulators | |
WO2012009009A3 (en) | Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors | |
JO3297B1 (ar) | تركيبات و طرق لتعديل fxr | |
JO3475B1 (ar) | ناهضات مستقبل سوماتوستاتين نوع فرعي 4 (sstr4) جديدة | |
BR112012013431A8 (pt) | composto, composição farmacêutica e seu uso | |
TN2011000585A1 (en) | Lxr modulators | |
IN2012DN05125A (uk) | ||
MY183111A (en) | 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators | |
MX2011006132A (es) | Imidazol carboxamidas fusionadas como moduladores de trpv3. | |
MX2011006821A (es) | Derivados de imidazol fusionados como antagonistas de trpv3. | |
MX2010005704A (es) | Derivados de cromano como modulares del trpv3. | |
MX2013006768A (es) | Moduladores de receptor de glucagon. | |
MX2012007005A (es) | Tiazoles biciclicos como moduladores alostericos de recptores de glutamato metabotropico subtipo 5. | |
ATE512142T1 (de) | Pyrimidin- und chinazolinderivate als modulatoren der somatostatin-rezeptor aktivität | |
UA104861C2 (uk) | Похідні хроману як модулятори trpv3 | |
EA201390055A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОПИРАЗОЛО[3,4-b]АЗЕПИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ МЕТАБОТРОПНЫХ ГЛУТАМАТНЫХ РЕЦЕПТОРОВ | |
MX2011008126A (es) | Compuestos de indol sustituidos como moduladores del receptor 1 de bradiquinina. | |
MX2012007006A (es) | Tiazoles biciclicos como moduladores alostericos de receptores mglur5. | |
EA201190003A1 (ru) | Производные хроменона в качестве trpv3 антагонистов | |
MY152686A (en) | Thienopyrimidinedione derivative as trpa1 modulators | |
MY156778A (en) | Fused pyrimidinedione derivatives as trpa1 modulators |